Sarepta Therapeutics Inc. (NASDAQ:SRPT)‘s stock had its “outperform” rating restated by analysts at Oppenheimer Holdings Inc. in a research report issued on Monday. They presently have a $76.00 price objective on the stock. Oppenheimer Holdings Inc.’s price target indicates a potential upside of 52.37% from the company’s previous close.
Several other research analysts have also recently issued reports on SRPT. Vetr upgraded Sarepta Therapeutics from a “sell” rating to a “hold” rating and set a $17.28 price objective for the company in a research report on Monday, June 20th. Wedbush reissued an “outperform” rating and issued a $36.00 target price on shares of Sarepta Therapeutics in a report on Wednesday, June 22nd. Jefferies Group reissued an “underperform” rating and issued a $7.00 target price on shares of Sarepta Therapeutics in a report on Saturday, June 25th. William Blair reissued a “market perform” rating on shares of Sarepta Therapeutics in a report on Monday, June 27th. Finally, Robert W. Baird reissued an “outperform” rating and issued a $23.00 target price on shares of Sarepta Therapeutics in a report on Monday, June 27th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating, fourteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average price target of $63.54.
Shares of Sarepta Therapeutics (NASDAQ:SRPT) opened at 49.88 on Monday. Sarepta Therapeutics has a one year low of $8.00 and a one year high of $63.73. The company has a 50-day moving average of $46.30 and a 200 day moving average of $27.13. The stock’s market capitalization is $2.39 billion.
Sarepta Therapeutics (NASDAQ:SRPT) last released its quarterly earnings data on Tuesday, July 19th. The company reported ($1.35) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.19) by $0.16. During the same period in the previous year, the firm posted ($0.87) earnings per share. Equities research analysts forecast that Sarepta Therapeutics will post ($4.23) earnings per share for the current fiscal year.
In related news, VP Jayant Aphale sold 35,000 shares of the firm’s stock in a transaction dated Monday, September 19th. The stock was sold at an average price of $50.00, for a total transaction of $1,750,000.00. Following the sale, the vice president now directly owns 21,490 shares in the company, valued at approximately $1,074,500. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, CEO Edward M. Md Kaye sold 24,557 shares of the firm’s stock in a transaction dated Wednesday, September 14th. The shares were sold at an average price of $30.00, for a total value of $736,710.00. Following the sale, the chief executive officer now owns 76,983 shares in the company, valued at $2,309,490. The disclosure for this sale can be found here. Corporate insiders own 10.90% of the company’s stock.
Large investors have recently made changes to their positions in the stock. Emerald Mutual Fund Advisers Trust bought a new stake in shares of Sarepta Therapeutics during the second quarter valued at approximately $4,712,000. First Midwest Bank Trust Division increased its stake in shares of Sarepta Therapeutics by 36.2% in the second quarter. First Midwest Bank Trust Division now owns 32,954 shares of the company’s stock valued at $628,000 after buying an additional 8,754 shares during the last quarter. American Century Companies Inc. bought a new stake in shares of Sarepta Therapeutics during the second quarter valued at approximately $651,000. Eagle Asset Management Inc. bought a new stake in shares of Sarepta Therapeutics during the second quarter valued at approximately $6,756,000. Finally, Amici Capital LLC bought a new stake in shares of Sarepta Therapeutics during the first quarter valued at approximately $488,000. Institutional investors and hedge funds own 65.06% of the company’s stock.
Sarepta Therapeutics Company Profile
Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery and development of ribonucleic acid (RNA)-targeted therapeutics for the treatment of rare, infectious and other diseases. The Company operates in one segment: the development of pharmaceutical products on its own behalf or in collaboration with others.
Receive News & Ratings for Sarepta Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.